Evrin

Indications for use

  • acute disorders of cerebral circulation (as part of combination therapy);

 

  • traumatic brain injury, sequelae of traumatic brain injury;

 

  • discirculatory encephalopathy;

 

  • syndrome of vegetative (neurocirculatory) dystonia;

 

  • mild cognitive disorders of atherosclerotic genesis;

 

  • anxiety disorders in neurotic and neurosis-like conditions;

 

  • acute myocardial infarction (from the first day) as part of combination therapy;

 

  • primary open-angle glaucoma of various stages, as part of combination therapy;

 

  • relief of abstinence syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

 

  • acute intoxication with antipsychotic drugs;

 

  • acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of combination therapy.

Therapeutic class:

Antioxidant agent

INN

Ethylmethylhydroxypyridine succinate

Market authorization in the following countries

Azerbaijan

Georgia

Back to catalog